RecruitingPhase 4NCT06184633

DUTCH Weight Control in Atrial Fibrillation Study

DUTCH Weight Control in Atrial Fibrillation Study, a Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Trial


Sponsor

Rijnstate Hospital

Enrollment

280 participants

Start Date

Jul 21, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Quantify the effect of an innovative weight loss management on rhythm control.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether a structured weight loss program can improve heart rhythm outcomes in people who have recently been diagnosed with a type of irregular heartbeat called persistent atrial fibrillation (AF). Obesity is known to worsen AF, and this trial explores whether losing weight helps. **You may be eligible if...** - You are 18 or older - You have been recently diagnosed with persistent atrial fibrillation (within the last 6 months) - You are obese (BMI of 30 or higher), or have a BMI of 27 or higher with a weight-related health condition like high blood pressure or diabetes - You are experiencing symptoms from atrial fibrillation **You may NOT be eligible if...** - You have had AF for a long time or previously treated AF - You have had heart surgery or a prior heart rhythm procedure - You have other serious heart conditions - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSemaglutide 3.2 MG/ML

Intervention arm receives semaglutide in addition to combined lifestyle intervention

DRUGPlacebo

Control arm receives placebo in addition to combined lifestyle intervention


Locations(1)

Rijnstate Hospital

Arnhem, Gelderland, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06184633


Related Trials